Multigene methylation analysis of Wilms' tumour and adult renal cell carcinoma

[1]  A. de la Chapelle,et al.  Hypermethylation, but not LOH, is associated with the low expression of MT1G and CRABP1 in papillary thyroid carcinoma , 2003, International journal of cancer.

[2]  J. Minna,et al.  NORE1A, a homologue of RASSF1A tumour suppressor gene is inactivated in human cancers , 2003, Oncogene.

[3]  F. Sato,et al.  Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. , 2002, Cancer cell.

[4]  W. Reik,et al.  Frequent RASSF1A tumour suppressor gene promoter methylation in Wilms' tumour and colorectal cancer , 2002, Oncogene.

[5]  P. Rustin,et al.  Functional consequences of a SDHB gene mutation in an apparently sporadic pheochromocytoma. , 2002, The Journal of clinical endocrinology and metabolism.

[6]  J. Minna,et al.  Establishment and validation of real-time polymerase chain reaction method for CDH1 promoter methylation. , 2002, The American journal of pathology.

[7]  Kenichi Harada,et al.  Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines , 2002, Oncogene.

[8]  C. Eng,et al.  RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours , 2001, Oncogene.

[9]  R. Dahiya,et al.  CpG methylation of promoter region inactivates E‐cadherin gene in renal cell carcinoma , 2001, Molecular carcinogenesis.

[10]  E S Husebye,et al.  Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. , 2001, American journal of human genetics.

[11]  G. Pfeifer,et al.  The CpG island of the novel tumor suppressor gene RASSF1A is intensely methylated in primary small cell lung carcinomas , 2001, Oncogene.

[12]  A. Protopopov,et al.  The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[13]  J. Minna,et al.  Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. , 2001, Journal of the National Cancer Institute.

[14]  J. Minna,et al.  Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours , 2001, Oncogene.

[15]  D. Haber,et al.  Wilms tumor and the WT1 gene. , 2001, Experimental cell research.

[16]  W. Bodmer,et al.  Hypermethylation of the promoter region of the E-cadherin gene (CDH1) in sporadic and ulcerative colitis associated colorectal cancer , 2001, Gut.

[17]  J. Minna,et al.  Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas. , 2001, Journal of the National Cancer Institute.

[18]  A. Eggert,et al.  Resistance to TRAIL-induced apoptosis in primitive neuroectodermal brain tumor cells correlates with a loss of caspase-8 expression , 2000, Oncogene.

[19]  D. Demetrick,et al.  Decreased expression of the INK4 family of cyclin‐dependent kinase inhibitors in Wilms tumor , 2000, Genes, chromosomes & cancer.

[20]  H. Höfler,et al.  Molecular analysis of E‐cadherin and cadherin‐11 in Wilms' tumours , 2000, The Journal of pathology.

[21]  M. Debiec‐Rychter,et al.  16q heterozygosity loss in Wilms' tumour in children and its clinical importance. , 2000, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[22]  J. Herman,et al.  CpG island methylator phenotype in colorectal cancer. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[23]  C. Wykoff,et al.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis , 1999, Nature.

[24]  P. Scambler,et al.  Loss of heterozygosity on chromosome 16 in sporadic Wilms' tumour. , 1998, British Journal of Cancer.

[25]  D. Sinnett,et al.  Demethylation by 5-aza-2´-deoxycytidine of specific 5-methylcytosine sites in the promoter region of the retinoic acid receptor ß gene in human colon carcinoma cells , 1998, Anti-cancer drugs.

[26]  M. Gessler,et al.  Allele loss in Wilms tumors of chromosome arms 11q, 16q, and 22q correlates with clinicopathological parameters , 1998, Genes, chromosomes & cancer.

[27]  S. Clifford,et al.  Inactivation of the von Hippel–Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: Evidence for a VHL‐independent pathway in clear cell renal tumourigenesis , 1998 .

[28]  N. Breslow,et al.  Clinicopathologic correlates of loss of heterozygosity in Wilm's tumor: a preliminary analysis. , 1996, Medical and pediatric oncology.

[29]  J. Herman,et al.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[30]  G. Gyapay,et al.  Characterization of regions of chromosomes 12 and 16 involved in nephroblastoma tumorigenesis , 1995, Genes, chromosomes & cancer.

[31]  A. Reeve,et al.  Epigenetic changes encompassing the IGF2/H19 locus associated with relaxation of IGF2 imprinting and silencing of H19 in Wilms tumor. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[32]  J. Herman,et al.  Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[33]  J. Herman,et al.  K-ras mutations and RASSF1A promoter methylation in colorectal cancer , 2002, Oncogene.